Introduction
Gene expression plays a critical role in the normal function of human cells. While changes in gene expression are normal for certain cell processes such as differentiation or activation, unintended changes in gene expression can lead to human disease. Altered gene expression is linked to two main events: (i) a change in the DNA sequence (such as a mutation, deletion, insertion, etc.) or (ii) a change in the local chromatin. While numerous mechanisms are known to cause a change in DNA sequence, the mechanisms that drive changes in chromatin structure are less understood. Chromatin refers to the protein-DNA complexes that interact in order to structure and compact two meters of DNA into one microscopic cell. Chromatin can exist as either euchromatin (uncompressed) or heterochromatin (compressed). These two states also correlate with the transcriptional activity of DNA, as regions of euchromatin tend to be transcriptionally active while heterochromatin tends to be transcriptionally inactive. The structure and transcriptional activity of chromatin is regulated in large part by DNA methylation and posttranslational modifications to histones, the major proteins that interact to form the nucleosomes around which DNA is compacted (1) . DNA methylation and histone modifications are capable of recruiting protein complexes that can maintain or change these chromatin marks and thereby alter the transcriptional activity of DNA (1) . Recent research suggests that noncoding RNAs (ncRNAs) are playing a role in the regulation of genes at the chromatin level by affecting DNA methylation and histone posttranslational modifications.
Two major pathways of RNA-based gene regulation have been characterized: (i) posttranscriptional gene silencing (PTGS) and (ii) transcriptional gene silencing (TGS). PTGS, originally observed in Caenorhabditis elegans, is a well-described pathway that acts at the mRNA level through an Argonaute-2 (Ago-2)-dependent mechanism and is commonly referred to as RNA interference (RNAi) (2) . Small interfering RNAs (siRNAs) act to recruit Ago-2 to a target messenger RNA (mRNA) through sequence complementarity. Recognition of the mRNA results in Ago-2-mediated cleavage or translational repression of the target mRNA and subsequently to decreased gene expression (2) . The mechanism of PTGS is transient and depends on the continued presence of the siRNA effector molecule. Loss of the effector molecule in the PTGS pathway eventually results in the return of normal gene expression (2) . In contrast to PTGS, TGS acts at the level of DNA and can result in long-term silencing. TGS involves ncRNA-mediated chromatin changes to a gene promoter, resulting in reduced transcription at the targeted locus. Chromatin modifications, including DNA methylation and histone methylation resulting from TGS-inducing RNAs, have been observed in plants (3) , Drosophila (4, 5) , and in the fission yeast Schizosaccharomyces pombe (6) . In 2004, TGS was observed in human cells when small RNAs targeted to the promoter of elongation factor 1α were shown to induce gene silencing (7) .
Mechanistic detai ls of sma l l RNA-directed TGS in human cells have begun to emerge. Numerous new studies over the past 6 years have significantly advanced our understanding of TGS in mammalian cells while raising an important question: how much do we really know about the role of RNA in gene regulation? Recent genomewide studies have revealed that transcription of ncRNAs is far more ubiquitous than previously thought. Furthermore, new research indicates that ncRNAs may also have the ability to cause gene activation, the exact opposite form of gene regulation observed in PTGS and TGS. This review will detail current research regarding gene regulation by ncRNAs and highlight commonly used techniques in the field that have significantly aided in the study of this molecular process. In addition, the potential for therapeutic applications based on ncRNA regulation and the need for novel delivery methods will also be discussed.
TGS by small RNAs
The first studies of TGS used small RNAs targeted to various gene promoters to induce gene silencing. RNAs used to target gene promoters have included synthetic siRNAs
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The RNA World www.BioTechniques.com x Vol. 48 | No. 6 | 2010 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) and plasmids expressing short hairpin RNAs (shRNAs) (8, 11, (19) (20) (21) or small antisense RNAs (8, 22) from RNA polymerase III (RNA Pol III) promoters ( Figure 1 ). RNA Pol III is responsible for transcribing various ncRNAs in the cell such as ribosomal RNA and transfer RNAs. As such, RNA Pol III binding promoters including the human U6 small nuclear RNA or the human H1 are commonly used to express ncRNAs due to the short recognition and termination sequences and characterized initiation sites. One of the defining characteristics of TGS is the ability of promoter-targeted small RNAs to reduce mRNA levels of a gene by reducing the amount of transcriptional initiation. Levels of transcription are determined by using quantitative real-time PCR (qRT-PCR) to amplify reverse-transcribed cellular RNA, thereby identifying whether a targeted gene has been affected. While a critical tool, qRT-PCR cannot differentiate between decreases in transcription due to less initiation (as in TGS) versus degradation of mRNA (as in PTGS). Therefore, it is critical to initially assess the action of small RNAs involved in TGS using nuclear run-ons, in which active transcription is halted and then resumed in the presence of labeled UTP, often 32 P or biotin (7, 10, 18, 20, 22, 23) . The labeled RNA is most commonly analyzed by dot blot to determine the level of transcription at a target gene compared with a control gene. Using qRT-PCR and nuclear run-ons as initial assays, promoter-targeted small RNAs generated de novo have been shown to reduce the transcriptional activity of numerous genes.
Another defining characteristic of TGS is the ability of small RNAs to direct chromatin changes such as histone methylation (7) (8) (9) 11, 15, 16, 18, 20, (22) (23) (24) and/or DNA methylation (7, 10, (19) (20) (21) (22) 25) to targeted gene promoter loci. These modifications suggest the chromatin structure is being altered at the targeted gene, thereby reducing initiation of transcription. Chromatin changes in TGS are dependent on the interaction between the promoter-targeted small antisense RNA and a low-copy promoter-associated RNA (pRNA), which is transcribed by RNA polymerase II (RNA Pol II) (8, 15, 16, 20) (Figure 1) . Degradation of the pRNA using complementary phosphorothioatemodified DNA oligonucleotides, which activate the RNase H pathway, resulted in the loss of the ability of TGS-inducing RNAs to mediate histone methylation (15) . Chromatin immunoprecipitations (ChIPs) performed by incubating primary antibodies against various histone modifications with sonicated cell nuclei have allowed researchers to observe the local chromatin state around a targeted gene. Increases in histone 3 lysine 27 trimethylation (H3K27me3) and histone 3 lysine 9 dimethylation (H3K9me2) are frequently induced in TGS, modifications that are known to associate with transcriptionally silent heterochromatin regions in DNA (1) . DNA methylation, also associated with reduced transcriptional activity, occurs at cytosine-phosphate-guanine (CpG) residues, which tend to be enriched at gene promoters (26) . Bisulfite treatment of cellular DNA results in the deamination of unmethylated cytosines, while methylated cytosines are protected. Various techniques can be used to analyze the level of DNA methylation; however, the simplest is still to use PCR on treated DNA followed by sequencing. This technique has been used to link promoter-targeted small RNA targeting to DNA methylation, further defining the mechanism of TGS.
While most promoter-targeting RNAs bind upstream of the transcriptional start site (TSS), some groups have noted that targeting promoters at or very near to the TSS also induces TGS (14, 17) . In these cases, however, DNA and histone methylation do not appear to be involved (12, 13, 17) . This has led to the proposal of an alternate mechanism for TGS by which small RNAs targeted to the TSS block the procession (14) and/or recruitment of RNA Pol II (17) . Interestingly, a genome-wide study of nucleosome positioning in the yeast Saccharomyces cerevisiae showed that transcriptional start sites were generally devoid of nucleosomes (27) . This observation suggests that small RNAs that target the TSS may be too distant from nucleosomes to induce the histone modifications observed with small RNAs that target upstream of the TSS.
The enzymes responsible for the chromatin changes observed in TGS have been identified using techniques including ChIPs, modified ChIPs, and traditional PTGS RNAi. Current research has consistently shown the involvement of one protein, human Argonaute-1 (Ago-1), in siRNA-or small antisense RNA-mediated TGS (9, 11, 13, 16, 20, 22, 24) (Figure 1 ). Knockdown of Ago-1 using RNAi results in the abolishment of TGS; however, direct evidence that Ago-1 binds TGS-inducing small RNAs remains to be shown. Other proteins observed in some, but not all, TGS systems include Ago-2 (13, 16, 20, 22) , trans-activation response (TAR)-RNA binding protein 2 (TRBP2) (11) , and the histone methyltransferase Ezh2 (11, 20, 22) . Furthermore, histone deacetylase 1 (HDAC1) (9, 20, 22) and the de novo DNA methyltransferase 3A (DNMT3A) (8, 20, 22) appear to be responsible for histone-and DNA-related changes, respectively ( Figure 1 ). DNMT3A has previously been shown to bind RNA (8, 28) and, in one study (8) , specifically bind a gene-silencing small RNA as observed through an RNA immunoprecipitation assay. DNMT3A has also been shown to associate with Ezh2 (29) and HDAC-1 (30) , indicating the possible recruitment of a chromatin remodeling complex that associates with Ago-1 at the targeted promoter to mediate the histone and DNA methylation observed in TGS. The observation that histone and DNA modifications are involved in TGS raises the possibility that small RNAs may be able to epigenetically silence targeted genes. Epigenetics refers to the study of heritable gene regulation by methods other than changes in the DNA sequence, such as the modifications to the chromatin structure observed in TGS. While it is well known that DNA methylation can be maintained through successive generations, recent research suggests that patterns of histone posttranslational modifications may also be conserved (1, 31, 32) . While evidence of the ability of small RNAs to induce permanent epigenetic changes is limited, one study has shown small RNAs can induce heritable changes in gene expression. In this study, researchers generated a cell line that stably expressed a tetracycline-inducible shRNA targeted to the ubiquitin C (UBC) promoter (20) . Induced expression of this shRNA for 4 days, followed by removal of tetracycline, resulted in long-term silencing of UBC expression for 1 month (20) . DNA methylation at the UBC promoter was established after 4 days of targeting by DNMT3A; however, maintenance of methylation over multiple cell generations was linked to DNA methyltransferase 1 (DNMT1) (20) , which maintains methylation patterns by methylating hemimethylated DNA. These results suggest that small RNAs are capable of epigenetically regulating gene expression and result in long-term silencing of a gene.
In 2008, two groups identified endogenous microRNAs (miRNAs) capable of mediating TGS (16, 24) . Both approaches used bioinformatics to identify potential miRNA binding sites within gene promoters, with one group focusing on two specific miRNAs (16) while the other performed a more general search (24) . Both studies observed the recruitment of Ago-1 and histone methylation to the targeted promoters (16, 24) . The specificity of miRNA-induced TGS remains unknown, as miRNAs acting in a PTGS manner have the ability to target numerous transcripts and do not require exact complementarity to the target sequence (33) . Indeed, one of these studies observed that TGS-inducing miRNAs led to the transcriptional regulation of 4 out of 5 genes chosen at random from a pool of 104 potential target genes (16 
Transcriptional gene activation by small RNAs
Gene activation in human cells was first observed when siRNAs targeted to the promoters of E-cadherin, vascular endothelial growth factor (VEGF), and p21 were observed to increase mRNA and protein levels of these genes (34) . A reduction in H3K9me2 and a requirement for Ago-2 were observed in this system, indicating a very different mechanism from TGS (34) . The ability of these siRNAs to activate rather than suppress gene expression was attributed to the target sequence in the promoter. While most silencing siRNAs targeted GC-rich regions, these siRNAs targeted AU-rich regions of the promoter (34) . In a second study, a group targeting the progesterone receptor (PR) also observed that certain promoter-targeted small RNAs resulted in gene activation, demonstrated by qRT-PCR and protein blot analysis (35) . Similarly, it was observed that RNAs that activated the PR also tended to be AU-rich at certain positions and resulted in changes to the local histone profile, including increased methylation of histone 3 lysine 4, which is a mark associated with transcriptionally active chromatin (35) . Two years after the initial report of small RNA-mediated gene activation, it was reported that the miRNA miR-373 could target the promoter of E-cadherin and activate transcription. Place and colleagues initially screened the E-cadherin promoter for potential miRNA binding sites and found a target site for miR373 (36) . Chemically synthesized processed and unprocessed versions of miR-373 were transfected into cells and shown to result in activation of E-cadherin by qRT-PCR and protein blot (36) . A requirement for Dicer and an enrichment of RNA Pol II at the promoter of E-cadherin were also observed in miR-373 activation (36) . As miRNAs are known to have ubiquitous target sites when acting in a PTGS manner, a screen was also performed to determine if miR-373 could also be regulating other genes in addition to that for E-cadherin (36) . Of 12 genes screened, CSDC2 showed transcriptional activation (36) . These results suggest that miRNAs, which activate gene expression, similar to those acting in a TGS manner, lack specificity and have the ability to transcriptionally regulate numerous genes.
New observations have led to the proposal of a mechanism for gene activation by small RNAs. In a follow-up study by the Janowski group on their observation that small RNAs could activate the PR, they found that these small RNAs targeted an antisense transcript overlapping the PR promoter (37) (Figure 2 ). They observed direct binding of the small activating RNA to the antisense transcript by individually biotinylating each strand of the small RNA and subjecting nuclear lysates to a streptavidin pulldown (37). Reverse transcription followed by PCR analysis of eluates from the streptavidin pulldown showed that an antisense PR RNA interacted with the biotinylated sense strand of the small RNA (37) . The involvement of Argonaute proteins in activation was also observed; however, a specific Argonaute protein was not identified (37) . In a second study by a group using the same siRNAs used by Li et al. (34) , researchers observed that the promoter-targeted siRNAs did not target the p21 promoter, but that activation was an off-target effect of the siRNA binding and cleaving an antisense RNA overlapping the p21 mRNA (38) . When an siRNA was designed with complete complementarity to the p21 antisense RNA, Ago-2-dependent degradation of the antisense RNA and activation of the p21 gene was observed (38) (Figure 2 , E and F). While this study focused on p21, it was noted that the activating E-cadherin dsRNA (34) and miR-373 (36) were also capable of binding an antisense transcript specific for E-cadherin (38) . These observations suggest that, in one mechanistic interpretation, RNA activation occurs due to the targeting and repression of an endogenous repressor RNA.
Most recently, the Li group has followed up on their initial observations that promotertargeted small RNAs can activate gene expression by examining activation in other mammalian cell lines including nonhuman primate, mouse, and rat (39) . Their results replicated activation of E-cadherin, VEGF, and p21 in these various cell lines and showed targeting and activation of new genes, suggesting the mechanism of gene activation is conserved in other mammals (39) . While the mechanisms of both TGS and activation remain incomplete, continued research will only further our understanding of RNA-mediated transcriptional regulation.
Gene regulation by long ncRNAs
While studies have demonstrated the ability of small RNAs to regulate gene expression, questions have remained. Is this pathway active in human cells and, if so, what are the natural effector molecules? In this regard, a role for bidirectional transcription in ncRNAmediated gene regulation has emerged. The existence of transcription antisense to coding regions has long been studied and proposed as a form of gene regulation (40) (41) (42) (43) (44) . Furthermore, as discussed earlier, the targeting of antisense RNAs overlapping promoter regions by small RNAs resulted in the activation of gene expression (37, 38, 45) (Figure 2, E and F) . Indeed, while small RNAs were being used to target gene promoters, researchers were observing that long ncRNAs were playing a role in the silencing of certain developmentally important genes. Even prior to the discovery that small RNAs could silence gene expression, it was known that a long ncRNA played a role in X-inactivation in mammals. X-inactivation is responsible for silencing one of the X chromosomes in females in order to equalize gene expression with males (46) . Two long ncRNAs, RepA and Xist, are responsible for initiation and maintenance of X-inactivation by directing a chromatin-modifying complex to the silenced chromosome, resulting in histone methylation and heterochromatin formation (46) . RepA initially recruits polycomb-repressive complex 2 (PRC2), a polycomb group (PcG) complex that mediates histone methylation, followed by spreading of the PRC2 complex across the chromosome by Xist (46) . PRC2 is largely formed by the proteins Ezh2, EED, and Suv12, which mediate methylation primarily at histone 3 lysine 27 (47) . Interestingly, polycomb protein Ezh2 has been shown to act as a recruiter of DNA methyltransferases including DNMT3A (29), while EED has been shown to interact with histone deacetylases including HDAC1 (48) . Both DNMT3A and HDAC1 have also been implicated in small RNA-induced TGS, indicating a potential link between PcG-mediated repression and TGS. The Xist RNA is itself regulated by another ncRNA, Tsix, which acts to repress Xist expression on the active X chromosome by inducing DNA methylation at the Xist promoter (46) .
In another example, the differential expression of the human HOX loci has also been linked to regulation by ncRNAs. Using a custom DNA microarray, Rinn and colleagues examined the transcriptional profile of the four HOX loci in primary human fibroblasts (49) . The HOX loci in primary fibroblasts exhibit differential HOX expression depending on anatomical position, indicating developmental regulation and persistence of expression patterns over generations (49) . They observed a large amount of transcriptional activity that did not match potential coding sequences for the known HOX genes and identified the long ncRNA HOTAIR (HOX antisense intergenic RNA) (49) . Targeting of HOTAIR using RNAi resulted in transcriptional activation of the HOXD locus, loss of PcG protein Suz12, and loss of H3K27me3; these results are similar to the study that targeted the p21 antisense RNA (49) . In further examples of ncRNA regulation, the long ncRNAs Air (expressed from the second intron of the mouse igf2r gene) and kcnq1lot1 (expressed from intron 10 of the mouse kcnq1 gene) have both been shown to silence nearby genes in cis in an allele-specific manner during mouse development (50) . Both ncRNAs have also been shown to direct H3K9me2 to the promoters of the silenced genes and recruit PcG proteins (50). While differences exist in the proposed mechanisms and the proteins involved, these observations, together with those of small RNA-mediated TGS and gene activation, strongly suggest that long ncRNAs may be the endogenous effector molecules of TGS and are active regulators of gene expression in human cells.
The studies detailed above have only scratched the surface of ncRNA-mediated gene regulation. Published in December of 2008, four papers described the transcriptome of mammalian cells and demonstrated that antisense transcription is more widespread than previously believed (51) (52) (53) (54) . It was also observed that antisense transcription is not random, but was found at a higher abundance around promoters of known coding regions (51) (52) (53) (54) . Antisense transcription was also found to be associated with promoters containing CpG islands (51) . Independently, increased DNA methylation at a promoter known to be regulated by an antisense RNA was observed upon depletion of the RNA exosome from cells (53) . In later genome-wide studies by the group that identified HOTAIR, potential long ncRNA coding regions were identified by examining chromatin maps of various human cell lines for a specific chromatin pattern. They showed that the presence of histone 3 lysine 4 trimethylation (H3K4me3) followed by a region of histone 3 lysine 36 trimethylation (H3K36me3) was indicative of promoter and transcribed regions, respectively (55, 56) . By removing those RNAs with known or potential coding regions, they observed numerous transcribed regions that appeared to be long ncRNAs (55, 56) . Use of inducers of certain cell responses, such as DNA damage and Toll-like receptor (TLR) activation, resulted in changes in the expression profiles of these ncRNAs (55) . Furthermore, binding of long ncRNAs to Suz12 and Ezh2, members of the PRC2 PcG repressive complex, was observed using RNA immunoprecipitations (56) (Figure 2, B-D) . RNAi knockdown of Suz12 and Ezh2 led to an upregulation of various gene sets (56) . The altered gene expression was proposed to result from the inability of regulatory ncRNAs to recruit the Suz12-and Ezh2-containing PRC2 complex to transcriptionally silence these genes (56) . The growing number of ncRNAs involved in controlling gene expression suggests we are just beginning to appreciate the role that RNA and transcription play in the cell.
The future of RNAbased gene silencing terized that hypo-and hypermethylation of tumor suppressor genes can lead to the development of cancer (57, 58) . In these cases, gene expression is either activated or suppressed due to the methylation state of the gene promoter (57, 58) . While expression of DNA methyltransferases has been observed to be altered in some tumor models, the mechanism that leads to the hypo-or hypermethylation remains unknown (57, 58) . In a seminal study, researchers used strand-specific, directional reverse transcriptase PCR to show that the tumor suppressor gene p15 has an overlapping RNA transcript antisense to the p15 mRNA (45) . When samples of patients with two specific types of leukemia, in which p15 is commonly observed to be epigenetically silenced, were examined, researchers found that 69% of patients showed increased p15 antisense levels and decreased p15 expression levels (45). Yu and colleagues showed that overexpression of a cytomegalovirus (CMV)-driven p15 antisense RNA construct led to increased H3K9me2 and hypermethylation at the p15 promoter (45) (Figure 2, B-D) . Overexpression of the p15 antisense RNA in mouse embryonic stem cells led to H3K9me2 enrichment followed by increased DNA methylation, implicating heterochromatin formation through histone modifications as the primary event (45) . This represents the first example that a disruption in the expression pattern of a long ncRNA can lead to a characteristic observed in human disease.
The observation that p15 can be epigenetically regulated by an antisense ncRNA suggests a new model for the initiation of epigenetic changes in cancer. It was also noted by Guttman and colleagues that long ncRNAs identified by their genome-wide scans tended to be associated with transcription factors, proteins that are often also labeled as tumor suppressor genes (55) . These observations suggest a new area for therapeutic targeting, as changes in the expression profile of ncRNAs should be examined as potential inducers of cancer. The Food and Drug Administration (FDA)-approved histone deacetylase inhibitors and DNA methyltransferase inhibitors are currently being used clinically to reverse epigenetic silencing of genes in certain cancers (57, 59) . Therapy of small RNAs that target transcripts to either activate or suppress, in combination with drugs that inhibit chromatin-modifying proteins, may represent a new method to treat cancers caused by epigenetic changes. Furthermore, continued treatment with gene-specific RNAs could maintain the appropriate chromatin state without needing additional treatment by drugs that can have nonspecific and toxic side effects. Small RNA therapies are not limited to cancer, as small RNAs are also being used to target human immunodeficiency virus (HIV) in a TGS manner (9, 10, 22) . These studies suggest that targeting of small RNAs to the HIV-1 promoter that induce histone and DNA methylation have the ability to suppress viral production, raising hopes that a new class of drugs could be developed that target a disease that has rapidly evolved to evade the numerous small-molecule drugs currently available (9, 10, 22) . The therapeutic applications are currently endless in this new field of RNA-based regulation, but drug development is limited by one bottleneck: delivery.
It is well known that unmodified RNA is highly unstable in serum, prone to hydrolysis, and subject to nuclease attack, which reduces effectiveness (60) . Numerous chemical modifications have been introduced that have significantly improved the stability of RNA. These modifications focus on modifying either the nonbridging oxygen of the phosphate backbone or the 2′-hydroxyl of the ribose sugar, both of which are needed for nuclease degradation of RNA (60) . Common changes include sulfur (phosphorothioate), boron (boranophosphate), or methyl (methylphosphonate) modifications of the backbone and fluorine (2′-fluoro), methyl (2′-O-methyl), methoxyethyl (2′-O-MOE), or 2′O-4′C bridge (locked nucleic acid, or LNA) modifications of the ribose, among others (60) . While stability has been improved, delivery mechanisms to introduce the RNA into cells also remain under development. Nonviral methods of delivery, including lipid-and polymer-based nanoparticles, have been tested in vivo for systemic delivery; however, limitations including toxicity and difficulty delivering RNA to specific target cells linger (61, 62) . Viral delivery using lentiviral and retroviral vectors are under investigation for delivery of ncRNAs as a form of gene therapy; some are already in clinical trials as therapies for HIV (63) . While significant strides have been made to improve the safety of lentiviral vectors, concerns about recombination and the permanent nature of integration required by these viral delivery mechanisms remain major obstacles in their development as delivery mechanisms for diseases other than HIV (64) . The emphasis on continued basic research to fully characterize the mechanism of RNA-based gene regulation, coupled with the development of novel delivery mechanisms, will no doubt significantly propel the use of RNAs in the clinic.
